Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 561 posts found.

Sanofi and SIRION collaborate on AAV vector development to treat serious diseases

February 24, 2021
Research and Development AAV vectors, SIRION, Sanofi

SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.

News
libtayo

FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer

February 23, 2021
Manufacturing and Production Cancer, Sanofi

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

News

GSK and Sanofi to begin new Phase II trial of their COVID-19 vaccine

February 22, 2021
Sales and Marketing COVID, COVID Vaccine, COVID-19, GSK, Sanofi

GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …

News
fdaoutsideweb

FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021
Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …

News
img_4190-e1376666350337-web

MHRA grants Promising Innovative Medicine Designation to Sanofi’s RSV drug

January 19, 2021
Manufacturing and Production MHRA, Sanofi

The MHRA has granted a Promising Innovative Medicine (PIM) Designation to Sanofi’s nirsevimab, which is being investigated a passive immunisation …

News

Sanofi to acquire Kymab for $1.1bn

January 11, 2021
Sales and Marketing Malin, Sanofi, kymab

Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to this upfront sum, Paris-headquartered Sanofi …

News
vaccination-1215279_960_720

Sanofi/GSK COVID-19 vaccine development delayed after failing to induce strong response in over-50s

December 11, 2020
Medical Communications, Research and Development COVID-19, GSK, Sanofi, Vaccine

Sanofi and GlaxoSmithKline have taken the decision to delay the development programme for their adjuvanted recombinant protein-based COVID-19 vaccine after …

News

Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis

November 30, 2020
Sales and Marketing Dupixent, EU, Europe, Sanofi

The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …

News

NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura

November 12, 2020
Sales and Marketing NHS, NICE, Sanofi, pharma

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

News
covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir

As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …

News
shutterstock_273326141

Sanofi angles to buy Kiadis for €308 million

November 2, 2020
Sales and Marketing Sanofi, kiadis, pharma

Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …

News
vaccination-1215279_960_720

GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative

October 28, 2020
Manufacturing and Production, Research and Development COVAX, COVID-19, GSK, Sanofi

Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

October 27, 2020
Manufacturing and Production Dupixent, Sanofi, pharma

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024